Helix BioPharma Corp.
TSX:HBP.TOBiotechnology
-$0.07 today
- Market cap
- $65.69M
- Beta
- -0.29
- P/E (TTM)
- -32.6
- EPS (TTM)
- -$0.04
Volume 0.00M
Average 0.00M
HBP.TO Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Helix BioPharma Corp.TSX: HBP.TO
Net Receivables · Q3 FY2026 · quarter ended Apr 2026
Net receivables falls 90.2% from a year ago
Net receivables stood at CA$28K at the end of Q3 FY2026, down 90.2% from a year earlier and up 12.0% from the prior quarter. Over 3 fiscal years it compounded at -24.3% a year.
Context
- Net receivables amounted to 0.1% of total assets at the end of Q3 FY2026, down 28.3 pp from a year earlier.
- Net receivables increased in 1 of the last 3 fiscal years.
What to watch
Whether net receivables keeps falling in the next quarterly balance sheet after a -90.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
CAD · from the balance sheet
- Latest · FY2025
- 121K CAD
- Year-over-year change
- +124.1%
- 4-year CAGR
- -23.5%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-07-31 | 121K | +124.1% |
| FY2024 | 2024-07-31 | 54K | -12.9% |
| FY2023 | 2023-07-31 | 62K | -77.8% |
| FY2022 | 2022-07-31 | 279K | -21.0% |
| FY2021 | 2021-07-31 | 353K | — |
Net Receivables vs competitors
How HBP.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -90.2% is the lowest of 5, against a peer median of +7.3%.
- Net receivables amounts to 0.1% of total assets for HBP.TO, versus a peer median of 3.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $8.14M USD | +16.6% | -11.2% | 6.2% | |
MSCL.TOSatellos Bioscience Inc. | Mar 2026 | $726.51K USD | +114.9% | +12.3% | 1.0% |
| Mar 2026 | CA$339.71K CAD | -2.0% | -22.2% | 1.1% | |
| Apr 2026 | CA$116.84K CAD | -73.0% | -52.5% | 7.6% | |
| Apr 2026 | CA$28K CAD | -90.2% | -24.3% | 0.1% | |
| Peer median (excluding HBP.TO) | — | +7.3% | -16.7% | 3.6% | |
Competitors are the stored peer set for HBP.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Helix BioPharma Corp.
TSX:HBP.TO
Intrinsic Alpha fair value
Locked
Current Price
$0.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.